search
Back to results

Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients

Primary Purpose

Septic Shock

Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Albumin 20% and terlipressin
Sponsored by
Amany Mousa Salama Muhammed
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring Microcirculation, Terlipressin, Human Albumin 20%

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The presence of septic shock meeting all of the following criteria less than 24 hours:-

    1. Clinically possible or probable or microbiologically confirmed infection taking into account the definitions of the "International Sepsis Forum (ISF)"
    2. Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mm Hg.
    3. Serum lactate level > 2 mmol/l (18 mg/dl) despite adequate volume therapy.

Exclusion Criteria:

  • Patients who failed to achieve target MAP despite adequate resuscitation with fluids and maximum dose of noreadrenaline.
  • Acute coronary artery disease or underlying cardiac dysfunction [cardiac index (CI) <2.2 l/min/m 2 ].
  • Severe liver disease (Child-Pugh grade C)
  • Chronic renal failure.
  • Known hypersensitivity to Norepinephrine, terlipressin and human albumin.
  • Those having Raynaud's phenomenon, or a vasospastic diathesis and
  • Other causes of shock e.g.; hemorrhagic hypovolaemia, cardiogenic shock, anaphylactic shock, neurogenic shock.
  • Pregnant patients and lactation.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Group AT

    Controlled

    Arm Description

    will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)

    will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).

    Outcomes

    Primary Outcome Measures

    Mean Flow Index 6hs
    Determination the degree the mean flow index (MFI) 6 hrs after administration albumin and terlipressin in patient with septic shock

    Secondary Outcome Measures

    Mean Flow Index 24hs
    Determination the degree the mean flow index (MFI) 24 hrs after administration albumin and terlipressin in patient with septic shock.

    Full Information

    First Posted
    September 29, 2021
    Last Updated
    October 13, 2021
    Sponsor
    Amany Mousa Salama Muhammed
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05080543
    Brief Title
    Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients
    Official Title
    Recruitment of Microcirculation Using Albumin 20% and Terlipressin in Patients With Septic Shock: a Randomized Controlled Double-blinded Study.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2021 (Anticipated)
    Primary Completion Date
    September 2022 (Anticipated)
    Study Completion Date
    October 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Amany Mousa Salama Muhammed

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The aim of this study is to evaluate the effect of combining HSA 20% and terlipressin on the microcirculation in patients with septic shock using the following;- Microcirculation recruitment by Cytocam-IDF. Cardiac output by LiDCOrapid. Measuring serum lactate level.
    Detailed Description
    Sepsis is one of the major medical problems and is responsible for high morbidity and mortality. Surviving Sepsis Campaign Guideline 2016 introduced 3-hours and 6-hours bundles in management of septic shock. The 2018 update of the Surviving Sepsis Campaign guidelines introduced the 'Hour-1 Bundle' which recommends treatment with intravenous fluids, measurement of serum lactate concentration as a marker of illness severity, administration of vasopressors, obtaining blood cultures and administering broad-spectrum antibiotics, all within the first hour. The usual targets for resuscitation of patients with septic shock are the macro-circulatory parameters such as mean arterial blood pressure and heart rate; however, it is believed that restoration of microcirculatory parameters is not sufficient to avoid organ failure unless it was associated with improved microcirculatory perfusion. The loss of coherence between macro- and micro-circulatory parameters increases the need to evaluate the microcirculatory blood flow. So impaired microvascular perfusion is increasingly recognized as a major determinant of tissue hypoxia during sepsis and is a key factor in the pathogenesis of sepsis-induced organ failure. Fluid resuscitation is recommended to be initiated immediately and completed within the first hour. Guidelines recommend at least a 30-mL/kg bolus of crystalloid fluid as the initial resuscitation. Crystalloid is the fluid of choice for initial resuscitation and subsequent intra-vascular volume replacement in patients with sepsis and septic shock. Albumin in addition to crystalloids is suggested when patients require a substantial amount of crystalloids. Although the guidelines make no recommendation regarding which concentration of albumin should be used, 5% albumin is most commonly used in patients with hypovolemia to administer as much volume as possible. In 2016, a study showed that in a rat model of normotensive endotoxemia, the infusion of 4% or 20% Human Serum Albumin "HSA" restored microvascular perfusion in otherwise unresuscitated animals. A more stable microvascular improvement noticed with 20% HSA. Sepsis is also characterized by an enhanced activation of inflammatory and oxidative stress pathways, which leads to endothelial dysfunction and vascular hyporeactivity. For its ability to counteract oxidative and nitrosative stress, albumin may represent not only a plasma expander but also an endothelium-modulating agent. In an experimental rodent model of endotoxemia, (HSA) prevented endothelial dysfunction and vascular hyporeactivity. In patients with septic shock requiring vasopressors, a targeted mean arterial pressure "MAP" of 65 mm Hg within the first hour is recommended. Norepinephrine is the recommended first-line vasopressor in septic shock. If MAP is not maintained at 65 mm Hg or greater with norepinephrine alone or if the norepinephrine dose needs to be decreased, either vasopressin (up to 0.03 unit/minute) or epinephrine can be added to norepinephrine. Although norepinephrine is widely regarded as the first-line vasoactive medication in sepsis, literature continues to debate whether the early addition of vasopressin should be common practice. Terlipressin is a synthetic analogue of vasopressin which has greater selectivity for the V1 receptor that cause vascular smooth muscle vasoconstriction in response to vasopressin and thus could be associated with fewer side effects than vasopressin. In 2016 a study showed that terlipressin therapy was associated with good improvement in hemodynamic variables and kidney functions more than adrenaline in patients with refractory septic shock despite adequate fluid resuscitation and the use of norepinephrine. No data was found on effect of combination of albumin and terlipressin on microcirculation in septic patients. This study aims to investigate the effect of this combination on microcirculation using Cytocam-IDF (incident dark-field illumination), Braedius.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Septic Shock
    Keywords
    Microcirculation, Terlipressin, Human Albumin 20%

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Model Description
    a randomized controlled and double-blinded
    Masking
    Investigator
    Allocation
    Randomized
    Enrollment
    36 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Group AT
    Arm Type
    Active Comparator
    Arm Description
    will receive a bolus of albumin (1gm/kg) and terlipressin loading dose of 1 mg over 20 minutes followed by infusion at rate (2 μ g/kg/h)
    Arm Title
    Controlled
    Arm Type
    Placebo Comparator
    Arm Description
    will receive the routine management of septic shock patients as culture-based IV antibiotics, IV fluids and intropic support plus a placebo (as lactated ringer solution in the same infusion rates for blinding).
    Intervention Type
    Drug
    Intervention Name(s)
    Albumin 20% and terlipressin
    Other Intervention Name(s)
    Microcirculation
    Intervention Description
    Evaluation the effect of adding 20% HSA and terlipressin on microvascular flow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
    Primary Outcome Measure Information:
    Title
    Mean Flow Index 6hs
    Description
    Determination the degree the mean flow index (MFI) 6 hrs after administration albumin and terlipressin in patient with septic shock
    Time Frame
    6 hrs
    Secondary Outcome Measure Information:
    Title
    Mean Flow Index 24hs
    Description
    Determination the degree the mean flow index (MFI) 24 hrs after administration albumin and terlipressin in patient with septic shock.
    Time Frame
    24 hs

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: The presence of septic shock meeting all of the following criteria less than 24 hours:- Clinically possible or probable or microbiologically confirmed infection taking into account the definitions of the "International Sepsis Forum (ISF)" Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mm Hg. Serum lactate level > 2 mmol/l (18 mg/dl) despite adequate volume therapy. Exclusion Criteria: Patients who failed to achieve target MAP despite adequate resuscitation with fluids and maximum dose of noreadrenaline. Acute coronary artery disease or underlying cardiac dysfunction [cardiac index (CI) <2.2 l/min/m 2 ]. Severe liver disease (Child-Pugh grade C) Chronic renal failure. Known hypersensitivity to Norepinephrine, terlipressin and human albumin. Those having Raynaud's phenomenon, or a vasospastic diathesis and Other causes of shock e.g.; hemorrhagic hypovolaemia, cardiogenic shock, anaphylactic shock, neurogenic shock. Pregnant patients and lactation.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Amany Mousa Salama, Assistant lecturer
    Phone
    +201004820018
    Email
    dr.amany.mousa@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Mohamed Sayed Arafa, Lecturer
    Phone
    +201003752053
    Email
    dr.3arafa1@gmail.com

    12. IPD Sharing Statement

    Learn more about this trial

    Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients

    We'll reach out to this number within 24 hrs